Breakthrough-Therapy-Designation-Progressive-Fibrosing-ILD

FDA Grants nintedanib Breakthrough Therapy Designation for Chronic Fibrosing ILDs with a Progressive PhenotypeThe designation was supported by results from the Phase III INBUILD ® study that met its primary endpoint and was recently published in the New England Journal of Medicine

Source: Boehringer Ingelheim Corporate News - October 10, 2019 Category: Research Source Type: news